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Background—Plasma free fatty acids (FFA) are higher in heart failure (HF) patients compared 
to healthy controls. Considering that the extent of FFA elevation in HF might mirror the severity of 
HF, we hypothesized that the serum levels of FFA may be a useful prognostic indicator for 3-
month mortality in acute heart failure (AHF).
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Methods—We analyzed the serum samples of AHF patients obtained at admission to the 
emergency department. Serum levels of FFA were analyzed using an enzymatic reagent on an 
automatic analyzer.
Results—Out of 152 included AHF patients that were originally included, serum samples of 132 
patients were available for the quantification of FFA. Of these, 35 (26.5%) died within 3 months of 
onset of AHF. These patients had significantly higher serum levels of FFA compared to AHF 
patients who were alive 3 months after onset of AHF. Univariable logistic regression analyses 
showed a significant positive association of FFA levels with 3-month mortality (odds ratio [OR] 
2.76 [95% confidence interval 1.32–6.27], p = 0.010). Importantly, this association remained 
significant after adjusting for age and sex, as well as for further clinical and laboratory parameters 
that showed a significant association with 3-month mortality in the univariate analyses.
Conclusions—We conclude that the admission serum levels of FFA are associated with 3-month 
mortality in AHF patients. Therefore, measurements of circulating FFA levels may help 
identifying high-risk AHF patients.
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Introduction
Heart failure (HF) is a final stage of various cardiovascular diseases and therefore a frequent 
cause of disability and death worldwide [1].
Hemodynamic impairment in HF triggers compensatory mechanisms causing 
neurohormonal and metabolic dysfunction, which contribute to the disease progression and 
severity [2]. Left ventricular dysfunction and heart congestion trigger a compensatory 
elevation of catecholamines and natriuretic peptides. By contrast, right-sided HF and the 
consequent peripheral venous congestion triggers a systemic inflammatory response [3, 4]. 
Increased serum levels of catecholamines, natriuretic peptides and inflammatory cytokines 
are the principal drivers of catabolic dominance, in particular adipose tissue lipolysis, the 
hallmark of metabolic dysfunction in HF [5, 6]. Free fatty acids (FFA) generated during 
lipolysis are transported to the liver, skeletal muscles and the heart, where they are used as 
an energy substrate. Consequently, the serum levels of FFA are determined by the rate of 
their generation and usage.
High concentrations of circulating FFA are potent inducers of insulin resistance and 
systemic metabolic impairment [7]. Elevated FFA have been shown to promote vascular 
oxidative stress and inflammatory response, both the known triggers and hallmark of 
endothelial dysfunction [8–10]. Together with an augmented myocardial FFA uptake and 
utilization as energy substrate, as well as excessive FFA storage in cardiomyocites, these 
may contribute to myocardial dysfunction [11, 12]. Plasma FFA have been found to be 
higher in HF patients compared to healthy controls [13] and raised in HF patients with 
reduced rather than preserved left ventricular ejection fraction (EF) [14].
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If the extent of FFA elevation in HF mirrors the hemodynamic impairment, then we 
hypothesized that the serum levels of FFA in the patients’ serum at admission may have a 
prognostic value for mortality in AHF. The aim of the present study was therefore to 
evaluate the prognostic value of the serum levels of FFA for 3-month mortality in AHF 
patients.
Materials and methods
Study design and patients
This was a prospective, observational single-center study in AHF. All subjects gave their 
informed consent for inclusion prior to participation in the study which was conducted in 
compliance with the ethical guidelines of the Declaration of Helsinki [15]. Ethics Committee 
approvals were obtained from the University Hospital Centre Sisters of Charity, Zagreb, 
Croatia (EP-15389/13-4) and the Medical University of Graz, Austria (29–266 ex 16/17). 
Patients with AHF as a primary diagnosis were recruited from the Emergency Department 
between November 2013 and February 2015. The diagnosis of AHF was established 
according to the ESC and ACCF/AHA Guidelines for HF by time of onset, final clinical 
presentation and ejection fraction (EF) [16–18]. Left ventricular EF was automatically 
calculated using the Simpson method. Patients with severe renal failure (serum creatinine 
≥400 μmol/L) renal replacement therapy, major systemic disease, severe hepatic cirrhosis 
(Child-Pugh Class B or C), neoplasms, acute or chronic inflammatory disease at admission, 
recent trauma or surgery, pregnancy or younger than 18 years were not included in the study. 
A further exclusion criterion was the patient’s choice not to participate in the study. One 
hundred and fifty-two included AHF patients were treated according to the ESC Guidelines 
for AHF [17, 18]. Hypertension was diagnosed according to the ESC criteria [19]. Mean 
arterial pressure (MAP) was calculated as (systolic + 2 · diastolic blood pressure)/3. Systolic 
pulmonary blood pressure (SPAP) was approximated by the tricuspid valve velocity, the 
estimated central vein pressure and the Bernoulli equation from a Doppler 
echocardiography. The New York Heart Association (NYHA) Functional Classification is 
estimated according to the severity of patients’ symptoms, and the differentiation of 
worsening vs. de novo cases was based on the patients’ history.
Laboratory procedures
The collection of the blood samples, and the standard laboratory methods, have already been 
described in previous reports on our AHF cohort [20–23]. Blood from the patients was 
obtained on admission to the hospital. The fasting status of the included AHF patients was 
unknown. Routine laboratory analyses including serum creatinine, urea, total cholesterol, 
low-density lipoprotein (LDL) cholesterol, high-density lipoprotein (HDL) cholesterol, 
triglycerides, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and C-
reactive protein (CRP) were measured using a Beckman Coulter instrument AU 2700, 2007 
(Brea, CA, USA) and Architect c8000, Abbott 2013 (Chicago, IL, USA). Serum levels of 
FFA were analyzed using an enzymatic reagent (ACS-ACOD method) from Wako 
Chemicals (Neuss, Germany) as described previously [24]. The measurements were 
performed on an Olympus AU640 automatic analyzer. Glomerular filtration rate (GFR) was 
estimated by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula 
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[25]. Interleukin-6 (IL-6) serum levels were determined using a specific chemiluminescent 
ELISA (QuantiGlo; R&D Systems, Wiesbaden-Nordenstadt, Germany). An 
electrochemiluminescence immunoassay with Elecsys e411 (Roche Diagnostics GmbH, 
Mannheim, Germany) was used for the quantification of N-terminal pro-brain natriuretic 
peptide (NT-proBNP). Blood cell counts and hemoglobin were measured in full blood 
supplemented with K3EDTA by an automatic analyzer DxH (Beckman Coulter).
Statistical analyses
FFA serum levels of patients who survived were compared with those who either died in the 
hospital or within 3 months after onset of AHF using the Mann-Whitney U-test. Correlations 
between FFA and various laboratory and clinical parameters were determined using 
Spearman’s correlation coefficient due to the skewed distribution of many of the laboratory 
parameters.
Univariable and multivariable logistic regression analyses were used to examine the impact 
of FFA on 3-month mortality. In the multivariable analyses, we adjusted for age and sex, as 
well as for further clinical and laboratory parameters that showed a significant association 
with 3-month mortality in the univariate analyses. Results are presented as odds ratio (OR) 
and the respective 95% CI. R version 3.4.4 was used for these analyses.
Results
Patients’ clinical characteristics and laboratory parameters
The baseline characteristics, comorbidities, medication, laboratory results and outcome of 
our 152 AHF patients have been described elsewhere [20–23]. The mean patient age was 
75.2 ± 10.3 years, with a range of 45.5–96.7, and 79 (52%) were female. Serum samples of 
132 patients were available for the analyses presented here. Of these, 35 (26.5%) died within 
3 months of onset of AHF. The median and range for serum FFA levels were 0.87 (0.13–
2.71) mmol/L. There was no difference between AHF patients with available FFA 
measurements and those without, with respect to baseline characteristics, laboratory 
parameters and comorbidities (Supplementary Tables S1–S3).
Correlation of FFA concentrations with laboratory and clinical parameters
As shown in Table 1, serum levels of FFA were significantly positively correlated with NT-
proBNP, ALT, AST and IL-6. However, the serum levels of FFA were not correlated with 
age, body mass index (BMI), MAP, glucose and several markers of kidney function. 
Furthermore, no significant correlation with the serum lipids was found, with the exception 
of HDL cholesterol, for which a significant negative correlation was observed.
Serum levels of FFA in AHF patients who died within 3 months after onset of AHF were 
higher compared to those who survived
Patients who died within 3 months after onset of AHF had significantly higher serum levels 
of FFA compared to AHF patients who were alive 3 months after onset of AHF (median and 
range: 0.74 [0.13–2.71] mmol/L vs. 1.05 [0.20–2.36] mmol/L, p = 0.004) (Figure 1).
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The univariable analyses showed that 3-month mortality was significantly positively 
associated with the serum levels of FFA, NT-proBNP, AST, ALT and IL-6, as well as 
significantly negatively associated with MAP, serum cholesterol levels and GFR (Table 2). 
Importantly, the association of the serum FFA levels with 3-month mortality remained 
significant after adjusting for age and sex as well as for the clinical and laboratory 
parameters which were significantly associated with 3-month mortality in the univariate 
analyses. Due to the high collinearity between AST and ALT, two different models were fit 
(Table 3).
Discussion
This study is the first that shows the association of serum levels of FFA with 3-month 
mortality in AHF patients. After adjusting for variables that were both known to influence 
the prognosis in HF and significantly associated with 3-month mortality in the univariate 
analyses in the present study, the association of FFA with 3-month mortality remained 
significant.
It is known that a decreased cardiac output and a subsequently decreased tissue perfusion as 
well as venous volume overload and congestion are accompanied by increased serum levels 
of catecholamines, natriuretic peptides and inflammatory cytokines, which are potent 
inducers of adipose tissue lipolysis [5, 6, 26]. The positive correlations of serum FFA with 
NT-proBNP and IL-6 that were observed in the present study substantiate the relationship 
between serum levels of FFA, the rate of adipose tissue lipolysis, and the severity of AHF. 
Therefore, it is reasonable to infer that the higher levels of FFA in AHF patients who died 
are simply a consequence of the severe stage of the disease itself associated with higher 
levels of catecholamines and natriuretic peptides as well as a more pronounced 
inflammatory response and insulin resistance. However, the capacity of elevated circulating 
FFA to increase the activity of the sympathetic nervous system [27, 28] suggests that FFA, 
which were initially increased as a consequence of hemodynamic and metabolic 
disturbances in HF, contribute to exaggeration of these pathophysiologic processes. This, 
together with the established detrimental effects of elevated FFA on the cardiovascular 
system as well as their role in cardiac lipotoxicity [8–12], suggests that elevated FFA play an 
active role in the HF pathophysiology. Indeed, previous studies have shown that an increased 
uptake of FFA into cardiac myocytes, secondary to the elevated FFA serum levels, 
diminishes glucose utilization and deteriorates cardiac ATP production [29]. In line with 
this, drugs which interfere with FFA utilization for energy production and shift substrate 
utilization towards glucose have been shown to exert positive effects on cardiac function in 
patients with chronic HF [30, 31]. Considering this and higher serum FFA levels in AHF 
patients who died within 3 months after the onset of AHF compared to those who survived, 
as observed in the present study, it is tempting to assume that the pharmacological inhibition 
of FFA utilization might improve cardiac function and reduce mortality in AHF.
In the present analysis, serum levels of FFA were also positively correlated with ALT and 
AST, whose increased serum levels indicate hepatocyte damage. Hepatocyte damage in HF 
is primarily due to liver hypoperfusion caused by a decreased cardiac output and to a lesser 
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extent due to passive hepatic congestion, a consequence of rightsided HF [32]. A healthy 
liver takes up substantial amounts of FFA that are liberated during lipolysis from the adipose 
tissue and uses them as fuel or substrate for ketone body synthesis. Compared to AHF 
patients who were alive, AST levels in the present study were significantly higher in AHF 
patients who died within 3 months after onset of AHF (median and range: 25.0 [10–666] 
U/L vs. 36.0 [14–487] U/L, p = 0.001). Accordingly, the increased FFA levels in AHF 
patients who died might at least in part be a consequence of the decreased FFA uptake by the 
liver, which was more damaged in patients who died compared to those that did not.
Additionally, the altered energy substrate preference of the failing heart, namely a shift from 
FFA to glucose [5, 33], may have been more pronounced in patients with a more severe 
disease. This may have contributed to the higher FFA serum levels in AHF patients who died 
within 3 months after onset of AHF compared to patients who survived.
There are several limitations to our present study: the design precludes drawing conclusions 
about cause and effect for the pathophysiological processes involved in the regulation of the 
serum levels of FFA. Moreover, we have no data on whether and how long patients were 
fasting before blood collection. Furthermore, due to missing values in the outcome as well as 
some of the regressor variables, data from only 117 patients was included in the 
multivariable regression model presented. The moderate number of available serum samples 
(n = 132) in this monocentric study influences the statistical power of our analyses. 
Therefore, larger studies are needed to confirm our results.
Conclusions
Based on our results, we conclude that admission serum levels of FFA are associated with 3-
month mortality in AHF patients. Therefore, measurements of circulating FFA levels might 
help identifying high risk AHF patients.
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Figure 1. Serum levels of FFA in AHF patients.
Difference between patients who died within 3 months after onset of AHF and those who 
survived.
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Table 1
Correlation analyses of FFA with clinical and laboratory parameters.
FFA, mmol/L
r p-Value n
Age, years   0.08 0.360 132
BMI, kg/m2 –0.12 0.185 132
MAP, mmHg –0.04 0.685 132
NT-proBNP, pg/mL   0.27 0.002 126
GFR, mL/min/1.73 m2 –0.04 0.690 131
Urea, mmol/L   0.14 0.111 131
Creatinine, mol/L   0.05 0.589 131
ALT, U/L   0.20 0.021 128
AST, U/L   0.24 0.005 129
IL-6, pg/mL   0.24 0.005 132
Total cholesterol, mmol/L –0.17 0.057 132
LDL cholesterol, mmol/L –0.13 0.126 132
HDL cholesterol, mmol/L –0.18 0.043 132
Triglycerides, mmol/L –0.05 0.542 132
Glucose, mmol/L –0.03 0.697 127
Data presented are the Spearman correlation coefficient r, the corresponding p-value, and number of available samples (n); significant correlations 
are depicted in bold. ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FFA, free fatty acids; GFR, 
glomerular filtration rate; HDL, high-density lipoprotein; IL-6, interleukin 6; LDL, low-density lipoprotein; MAP, mean arterial pressure; NT-
proBNP, N-terminal pro brain natriuretic peptide.
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Table 2
Univariable logistic regression analyses to assess the association of FFA and various 
clinical and laboratory parameters with 3-month mortality.
OR (95% CI) p-Value Events/n
FFA, mmol/L 2.89 (1.30–6.79) 0.010 35/127
Age, years 1.02 (0.98–1.07) 0.302 35/127
Sex 1.52 (0.70–3.37) 0.296 35/127
BMI, kg/m2 0.95 (0.88–1.02) 0.185 35/127
NT-proBNP, ng/mL 1.05 (1.02–1.09) 0.002 34/121
GFR, mL/min/1.73 m2 0.97 (0.95–0.99) 0.008 34/126
MAP, mmHg 0.98 (0.96–1.00) 0.030 35/127
EF, % 0.97 (0.94–1.01) 0.161 27/118
Cholesterol, mmol/L 0.65 (0.40–0.99) 0.029 35/127
LDL cholesterol, mmol/L 0.47 (0.14–1.36) 0.054 35/127
HDL cholesterol, mmol/L 0.66 (0.45–0.94) 0.204 35/127
Log(triglycerides), mmol/L 0.58 (0.20–1.54) 0.291 35/127
Glucose, mmol/L 0.94 (0.84–1.02) 0.187 34/123
AST, U/L 1.01 (1.00–1.02) 0.015 34/125
ALT, U/L 1.01 (1.00–1.02) 0.031 34/124
IL-6, pg/mL 1.01 (1.00–1.01) 0.030 35/127
T2D 0.93 (0.43–2.05) 0.859 35/126
Smoking 0.53 (0.18–1.34) 0.202 35/127
Significant associations are depicted in bold. ALT, alanine aminotransferase; AST, aspartate aminotransferase; AHF, acute heart failure; CI, 
confidence interval; CRP, C-reactive protein; EF, ejection fraction; FFA, free fatty acids; GFR, glomerular filtration rate; HDL, high-density 
lipoprotein; IL-6, interleukin-6; LDL, low-density lipoprotein; MAP, mean arterial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; 
OR, odds ratio; T2D, type 2 diabetes.
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Table 3
Multivariable logistic regression analyses of FFA and 3-month mortality.
OR (95% CI) p-Value Events/n
Model 1 2.94 (1.12–8.28) 0.033 32/118
Model 2 2.77 (1.06–7.75) 0.042 32/117
Model 1 was adjusted for age, sex, NT-proBNP, GFR, MAP, cholesterol, AST, and IL-6. Model 2 was adjusted for age, sex, NT-proBNP, GFR, 
MAP, cholesterol, ALT, and IL-6. ALT, alanine aminotransferase; AST, aspartate aminotransferase; CI, confidence interval; FFA, free fatty acids; 
GFR, glomerular filtration rate; IL-6, interleukin-6; MAP, mean arterial pressure; NT-proBNP, N-terminal pro brain natriuretic peptide; OR, odds 
ratio.
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